Blog
RSS FeedPosted by Michael Wonder on 20 Aug 2019
NICE’s track record in cancer drugs: the impact of the CDF and interim funding
20 August 2019 - Cancer drugs and the decisions made by the UK’s NICE have been subject to much scrutiny ...
Posted by Michael Wonder on 15 Aug 2019
Advanced ovarian cancer drug gets initial 'no' for NHS in England
15 August 2019 - A targeted drug with potential to slow the progress of ovarian cancer has been rejected for ...
Posted by Michael Wonder on 08 Aug 2019
New lung cancer treatment option approved by NICE
8 August 2019 - Another new life-extending treatment for some people with lung cancer is to be made available on the ...
Posted by Michael Wonder on 07 Aug 2019
NICE recommends additional treatment option for people with early breast cancer
7 August 2019 - NICE has today published draft guidance recommending neratinib as an additional treatment for some people with early ...
Posted by Michael Wonder on 26 Jul 2019
Innovative treatment for gynaecological cancers approved for Cancer Drugs Fund
26 July 2019 - Olaparib, a medicine that has previously been used at a later stage in the treatment of advanced ...
Posted by Michael Wonder on 08 Jul 2019
AstraZeneca boss calls for NHS drug approval shake-up
5 July 2019 - AstraZeneca has called for a wholesale review of the way new drugs are paid for in ...
Posted by Michael Wonder on 07 Jul 2019
AZ appeals against NICE rejection of Tagrisso in untreated lung cancer
5 July 2019 - AstraZeneca is appealing against NICE’s decision not to recommend funding for its lung cancer drug Tagrisso ...
Posted by Michael Wonder on 05 Jul 2019
Life-extending lung cancer treatment recommended for use on the NHS
5 July 2019 - Dacomitinib has been recommended as a first-line treatment option for people with a type of non-small-cell lung ...
Posted by Michael Wonder on 02 Jul 2019
Immediately after EU nod, England’s NHS funds Sanofi skin cancer drug
2 July 2019 - Patients in England will be among those who are first to benefit from Sanofi and Regeneron’s ...
Posted by Michael Wonder on 24 Jun 2019
England to fast-track tumour agnostic drugs like Vitrakvi – if the price is right
21 June 2019 - NHS England’s chief executive Simon Stevens was in Manchester this week at the NHS Confederation conference, ...
Posted by Michael Wonder on 19 Jun 2019
Game-changing cancer drugs which can attack all tumours will be fast-tracked by NHS
19 June 2019 - Game-changing cancer drugs which can attack all types of tumour will be fast-tracked by the NHS, ...
Posted by Michael Wonder on 19 Jun 2019
NICE nod for Blincyto
19 June 2019 - NICE has announced the recommendation of Amgen’s Blincyto (blinatumomab) for treating acute lymphoblastic leukaemia. ...
Posted by Michael Wonder on 18 May 2019
NICE recommends Revlimid as multiple myeloma alternative
17 May 2019 - NICE has recommended Revlimid (lenalidomide), a drug that helps to support the immune system to fight ...
Posted by Michael Wonder on 03 May 2019
NICE recommends Roche’s Tecentriq for metastatic NSCLC
3 May 2019 - NICE has published final draft guidance recommending Roche’s Tecentriq in combination with other therapies for metastatic ...
Posted by Michael Wonder on 10 Apr 2019
Novartis’ Kisqali hit with NICE rejection
10 April 2019 - NICE has issued a draft guidance which does not recommend Novartis’ Kisqali (ribociclib), which is typically ...